Dsuvia: A Dull US FDA Review Preceded The Controversial Approval
US FDA's review of AcelRx's opioid Dsuvia did not presage the external fireworks that came following the approval.

US FDA's review of AcelRx's opioid Dsuvia did not presage the external fireworks that came following the approval.